Asahi Kasei Acquires Aicuris Anti-infective Cures

Asahi Kasei has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million ($919 million). This transaction is expected to close in the first quarter of fiscal 2026. The acquisition expands Asahi Kasei's specialty pharmaceutical platform into severe infectious diseases, aligning with its strategy to build a focused and sustainable platform serving immunocompromised and medically complex patient populations. Aicuris brings three compounds, including Pritelivir and AIC468, which complement Asahi Kasei's existing portfolio and are expected to contribute to revenue growth and margin expansion. Ken Shinomiya, Head of Asahi Kasei's Healthcare Sector, emphasized that this acquisition strengthens their position across interconnected therapeutic areas and supports their objective of achieving ¥300 billion in pharmaceutical net sales by fiscal 2030.